Loading...

VTGN VISTAGEN THERAPEUTICS INC US FDA Inspections 8-K Filing

VSTG

VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)

2026 8-K

Director Departures

Financial Results Announcement

Clinical Program Update

New CMO Appointment

Positive Study Results

Clinical Trial Update

FDA Approval Update

Stock Options Granted

Audit Committee Update

Director Resignation

New Corporate Presentation

Workforce Reduction

Board Resignation

Financial Results Report

Non-Compliance Notice

New Corporate Presentation

Study Results Update

Management Change

Financial Results Update

Clinical Trial Update

Director Appointment

Management Changes

Financial Statements

Equity Offerings

Product Expansion

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Filing Letter with Quantita...

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Underwriting Agreement

Quantitative Data

Update on Progress and Fina...

Filing with Quantitative Data

Filing with Quantitative Data

Other Special Situation

Filing Letter with Financia...

Other Special Situation

Filing with Quantitative Data

Financial Update

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Other Special Situation

Filing Letter with Quantita...

Other Special Situation

Filing with Quantitative Data

Filing Letter with Quantita...

Update on Clinical Developm...

External Links:

On May 8, 2026, Vistagen Therapeutics, Inc. announced that their Phase 3 clinical trial for the fasedienol nasal spray for treating social anxiety disorder has completed its final patient visit.

AI Assistant

VISTAGEN THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.